DANIELLE E MARCOTULLI
Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology HACKENSACK, NJ NPI 1407220114
Browse related groups: Allopathic & Osteopathic Physicians|Internal Medicine|Hematology & Oncology NJ ABBVIE INC. All categories
General Payments — all program years on this page
$13,883.57
- Category: General Payments
- Program years: PY2021–2024
- Record count: 103
- As of (CMS publication): 2026-01-23
Latest program year (PY2024): $7,575.05 across 62 records · disputed records: 0
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How this figure is calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
Latest program year (PY2024) · sorted by reported total.
| Nature of payment | Amount | Records |
|---|---|---|
| Consulting Fee | $2,255.00 | 4 |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,000.00 | 2 |
| Travel and Lodging | $1,191.66 | 4 |
| Honoraria | $1,106.00 | 1 |
| Food and Beverage | $937.40 | 50 |
| Education | $84.99 | 1 |
By paying entity
Latest program year (PY2024) · sorted by reported total.
| Paying entity | Amount | Records |
|---|---|---|
| ABBVIE INC. | $2,797.51 | 11 |
| Astellas Pharma US Inc | $2,090.28 | 6 |
| Blueprint Medicines Corporation | $1,196.47 | 11 |
| NOVARTIS PHARMACEUTICALS CORPORATION | $725.11 | 4 |
| TAIHO ONCOLOGY, INC. | $271.35 | 5 |
| Takeda Pharmaceuticals U.S.A., Inc. | $108.04 | 2 |
| Celgene Corporation | $67.49 | 4 |
| Incyte Corporation | $54.20 | 3 |
| Daiichi Sankyo Inc. | $47.65 | 3 |
| PharmaEssentia USA Corporation | $46.77 | 3 |
| SOBI, INC | $34.61 | 2 |
| Rigel Pharmaceuticals, Inc. | $21.96 | 1 |
| GlaxoSmithKline, LLC. | $20.50 | 1 |
| Geron Corporation | $16.76 | 1 |
| PFIZER INC. | $16.35 | 1 |
| Genentech USA, Inc. | $16.13 | 1 |
| BARD PERIPHERAL VASCULAR, INC. | $14.90 | 1 |
| Adaptive Biotechnologies Corporation | $14.56 | 1 |
| Immunocore Limited | $14.41 | 1 |
By program year
Records — PY2024 (62)
Provenance & corrections
- Dataset: CMS Open Payments — General Payments
- Source: CMS Open Payments dataset (bulk file)
- Publisher of source data: Centers for Medicare & Medicaid Services
- Generated from: OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.